期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
2019新型冠状病毒基因组序列分析比对及其可能药物的寻找 被引量:10
1
作者 苏嘉洛 王康泓 杜成林 《华西医学》 CAS 2020年第3期269-273,共5页
2019新型冠状病毒具有潜伏周期长、传染性强、人群普遍易感的特点,目前没有特效药能较好地治疗新型冠状病毒肺炎。为增加对2019新型冠状病毒分子生物学水平的认知并尝试寻找有效治疗药物,该文利用SnapGene Viewer对由国家基因组科学数... 2019新型冠状病毒具有潜伏周期长、传染性强、人群普遍易感的特点,目前没有特效药能较好地治疗新型冠状病毒肺炎。为增加对2019新型冠状病毒分子生物学水平的认知并尝试寻找有效治疗药物,该文利用SnapGene Viewer对由国家基因组科学数据库发布的5株2019新型冠状病毒的基因组序列进行分析,得出该病毒的基因组长度约为29.8 kb,并预测了12个开放阅读框,发现开放阅读框中存在5个核苷酸变化的位点。此外,该文分析了严重急性呼吸综合征暴发时期使用药物、当前治疗新型冠状病毒肺炎的药物及其他可能药物等3个方面,以寻找部分具有临床治疗效果的可能药物。 展开更多
关键词 2019新型冠状病毒 序列分析 基因组 可能药物
原文传递
基于药物相互作用可能性量表客观评价临床药物相互作用 被引量:3
2
作者 潘莹 魏雪 +2 位作者 刘韬 周望 黄红兵 《今日药学》 CAS 2012年第3期148-150,155,共4页
药物相互作用已成为临床药学工作者日益关注的焦点,相关的临床案例报道不断增加,但大多缺乏一个客观的评价标准。本文引进国外通用的药物相互作用可能性量表(DIPS),并对量表中事项的评分规则、注意事项、应用以及局限性进行逐条解析,希... 药物相互作用已成为临床药学工作者日益关注的焦点,相关的临床案例报道不断增加,但大多缺乏一个客观的评价标准。本文引进国外通用的药物相互作用可能性量表(DIPS),并对量表中事项的评分规则、注意事项、应用以及局限性进行逐条解析,希望能为临床药师评价药物间相互作用与不良反应的因果关系提供一条客观的途径和统一的标准,有助于国内同行进行国际间案例交流。 展开更多
关键词 药物相互作用可能性量表 药物相互作用 因果关系 可能
下载PDF
Inhibitory effects of amiodarone on simvastatin metabolism in human liver microsomes
3
作者 Chao Wan Jiang wei Zhang Ning Zhu Ling Yang 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2009年第2期115-118,共4页
Objective To investigate the effects ofamiodarone (AMD) on simvastatin (SV) in human liver microsomes and the possible underlying mechanisms. Methods Time-, NADPH- and concentration-dependent inhibitions were test... Objective To investigate the effects ofamiodarone (AMD) on simvastatin (SV) in human liver microsomes and the possible underlying mechanisms. Methods Time-, NADPH- and concentration-dependent inhibitions were tested in HLM. The logarithm of relative inhibition values was plotted versus preincubation time (0, 5, 10, 15, 20min) for a series concentration of AMD used (0, 2, 5, 25, 50 umol/L), and the slopes determined by linear regression. These slope values represente the observed inactivation rate constants (kobs ). A double-reciprocal plot was then constructed using the reciprocal of the kobs (y-axis) and the reciprocal of the associated inhibitor concentration (x-axis) to estimate the values of kinact and K1, which were two principal kinetic constants that were specific for mechanism-based inhibition (MBI).drug-drug interactions (DDI) potential was predicted based on in vitro data and by using the in vitro-in vivo extrapolation. Results The time-, concentration- and NADPH-dependent characteristics confirmed that when SV was the substrate of CYP3A4, the inhibition of AMD to CYP3A4 is MBI. KI and kinact value were calculated to be 5.1umol/L and 0.018minL The CLant of SV was reduced 2.96-5.63 fold when it was administrated with AMD. Conclusion Based on the results, AMD would inhibit SV metabolism via the mechanism-based manner, which would lead to DDI when they are taken together. Careful clinical observation is recommended when AMD and SV have to be simultaneously prescribed. 展开更多
关键词 AMIODARONE SIMVASTATIN CYP3A4 drug-drug interaction mechanism-based inhibition
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部